supportive interventions for SCD have improved survival in children; yet disability and early death remain challenges in adulthood. Provider-related bias has been considered in the underutilization of disease-modifying therapies for SCD (e.g., Brandow and Panepinto 2010). Despite the availability of transplant in the US and France for over two decades, utilization remains heterogeneous across centers in both countries, despite similarities in patient population and health care access. Understanding these differences requires in-depth examination of institutional practices. Ethnographic research triangulated qualitative methods, including participantobservation, interviews and oral histories, and archival research. Fieldwork occurred over 30 months from 2012-15 and included two pediatric SCD centers in the US and two in France. Participant-observation and interviews were conducted in clinical settings and regional and international research and advocacy meetings. Interview participants included health care providers (25), adult patients (7), parents of children with SCD (19); additionally, 16 families were followed longitudinally over the course of their child's transplant. Fieldnotes and interviews were transcribed, coded, and analyzed using Atlas.ti data management software. Centers that were high utilizers of transplant employed multiple strategies to inform and refer families for treatment intensification. These practices were more uniform when a single provider managed a small clinic cohort, but were also observed in larger centers whose leadership worked to align provider clinical practice. Real time data collection and management of patient biometrics facilitated process control of treatment intensification in larger centers. The center whose providers were more atomized demonstrated greater heterogeneity in referral practices. Interviews and participant-observation revealed broad contingencies for provider comfort in initiating treatment intensification conversations with families. Responses from providers ranged from, "It's just information; why not tell them?" to refraining from discussions with patients altogether unless the case was discussed with other providers in the program. Of note, trusted non-physician members of the health care team provided significant support to families in centers that were high transplant utilizers. Biomedical ethical practice regularly outlines health care provider duties to inform patients of treatment options to facilitate autonomous decision-making. In this study, centers that regularly intensify treatment for SCD rarely provide "just information," but also incorporate multiple practice modalities to support families undergoing referral and evaluation for transplant.
Haploidentical transplantation with post-transplantation cyclophosphamide (PTCY) following marrow or peripheral blood stem cell (PBSC) graft has been associated with low incidence of graft-versus-host disease (GVHD) in adults. However, the data on PTCY based haploidentical HSCT in children is scarce and T cell depleted graft is still a favoured approach in children. We report on the outcome of 25 patients less than 20 years of age (median age-12 years; 2-20 years), undergoing a haploidentical PBSC transplantation for both malignant (n¼20) and non-malignant (n¼5) disorders. Patients with malignant diseases received myeloablative condition and this was nonmyeloablative for patients with non-malignant diseases. Engraftment was prompt and sustained, achieved at a median of 13 days. Cumulative incidences of acute GVHD and chronic GVHD were 40.3 % and 16.7 % respectively. On subgroup analysis, it was evident that acute GVHD developed in 80% of patients <10 years compared to only 13.3% in those between 10-20 years [log rank p¼0.0001], despite similar graft composition. The incidence of aGVHD 3-4 was 24% with all cases occurring in patients < 10 years old. CMV reactivation was documented in 80% of children < 10 years compared to 20% of the others. In patients > 10 years, only 3/15 patients had disease recurrence with no non-relapse mortality. Even though none of the 10 patients < 10 years had disease recurrence or graft failure, they experienced significantly higher non-relapse mortality due to GVHD related infections (76% vs 0 %; p¼0.001). The failure free survival was 59.5%; (79% in >10 years and 30% in < 10 years, p¼0.006). Our data suggested that PTCY based haploidentical PBSC transplantation is feasible in older children with excellent outcomes, but results in early and severe alloreactivity in younger children despite similar graft composition. These findings, despite being counterintuitive, could be explained by the variable metabolism of CY in young children compared to older ones or adults and indicates that PTCY based approach as used in adults might not be adequate for younger children. In view of the above findings, we have developed a novel approach on the PTCY platform to prevent early alloreactivity in younger children undergoing Haploidentical PBSC transplantation. We shall discuss the outline, rationale and preliminary findings of this on-going study.
